Eyconis, Inc
YongQi Mu currently serves as Vice President of Development Chemistry at Eyconis, Inc. since March 2024 and has held various leadership roles at Ascendis Pharma, including Senior Director & Head of Development Chemistry. Prior experience includes positions at Relypsa, where YongQi Mu progressed from Associate Director of Discovery Chemistry to Technical Operations, Strategy and Development. Additional roles include Senior Scientist at Nektar Therapeutics and Principal Scientist at Relypsa. YongQi Mu began a career in research at Theravance as a Research Scientist. Educational credentials include a Ph.D. in Medicinal Chemistry from Wayne State University, a postdoctoral degree from Stanford University, and a BS in Chemistry from Beijing Normal University.
This person is not in any teams
Eyconis, Inc
Eyconis, Inc. is a privately held, pre-clinical stage biopharmaceutical company focused on transforming the ophthalmology treatment paradigm through the development, manufacture, and commercialization of novel, best-in-class therapeutics for eye diseases. The Company is advancing a pipeline of therapeutic candidates addressing areas of high unmet need including wet age-related macular degeneration (AMD). Eyconis is partnered with a syndicate of leading biopharma investors including Frazier Life Sciences, RA Capital Management, venBio Partners, and HealthQuest Capital. The Company is headquartered in Redwood City, California, including research & development laboratories with scientific and manufacturing team members.